ExpressPoints
Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma—Experts Address the Paradox of Choice

Gain key clinical insights fast, with this short summary slideset from CCO on key considerations for optimal treatment selection for patients with relapsed/refractory myeloma.
Paul G. Richardson, MD
Program Director
Nina Shah, MD
Peter M. Voorhees, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.29 MB
Released: June 25, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm
Oncopeptides
Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings